Infectious Diseases and HIV Medicine
Publications
Inhibitor resistance in the KPC-2 beta-lactamase, a preeminent property of this class A beta-lactamase
Inhibitor resistance in the KPC-2 beta-lactamase
"Inhibitor resistance in the KPC-2 beta-lactamase, a preeminent property of this class A beta-lactamase"
Antimicrob Agents Chemother. 2010 Feb
Papp-Wallace KM, Bethel CR, Distler AM, Kasuboski C, Taracila M, Bonomo RA.
Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland
As resistance determinants, KPC beta-lactamases demonstrate a wide substrate spectrum that includes carbapenems, oxyimino-cephalosporins, and cephamycins. In addition, clinical strains harboring KPC-type beta-lactamases are often identified as resistant to standard beta-lactam-beta-lactamase inhibitor combinations in susceptibility testing. The KPC-2 carbapenemase presents a significant clinical challenge, as the mechanistic bases for KPC-2-associated phenotypes remain elusive. Here, we demonstrate resistance by KPC-2 to beta-lactamase inhibitors by determining that clavulanic acid, sulbactam, and tazobactam are hydrolyzed by KPC-2 with partition ratios (kcat/kinact ratios, where kinact is the rate constant of enzyme inactivation) of 2,500, 1,000, and 500, respectively. Methylidene penems that contain an sp2-hybridized C3 carboxylate and a bicyclic R1 side chain (dihydropyrazolo[1,5-c][1,3]thiazole [penem 1] and dihydropyrazolo[5,1-c][1,4]thiazine [penem 2]) are potent inhibitors: Km of penem 1, 0.06+/-0.01 microM, and Km of penem 2, 0.006+/-0.001 microM. We also demonstrate that penems 1 and 2 are mechanism-based inactivators, having partition ratios (kcat/kinact ratios) of 250 and 50, respectively. To understand the mechanism of inhibition by these penems, we generated molecular representations of both inhibitors in the active site of KPC-2. These models (i) suggest that penem 1 and penem 2 interact differently with active site residues, with the carbonyl of penem 2 being positioned outside the oxyanion hole and in a less favorable position for hydrolysis than that of penem 1, and (ii) support the kinetic observations that penem 2 is the better inhibitor (kinact/Km=6.5+/-0.6 microM(-1) s(-1)). We conclude that KPC-2 is unique among class A beta-lactamases in being able to readily hydrolyze clavulanic acid, sulbactam, and tazobactam. In contrast, penem-type beta-lactamase inhibitors, by exhibiting unique active site chemistry, may serve as an important scaffold for future development and offer an attractive alternative to our current beta-lactamase inhibitors.

- Division Chief Message
- News
- Publications
- Penicillin sulfone inhibitors of class D beta-lactamases
- In vitro activity of penem-1 in combination with beta-lactams against blaKPC-possessing Klebsiella pneumoniae isolates.
- Evaluation of an alcohol-based power sanitizing system
- Saline Nebulization before Gastric Lavage in the Diagnosis of Pulmonary Tuberculosis in Children and Adolescents
- Preserved MHC class II antigen processing in monocytes from HIV-infected individuals
- Acinetobacter baumannii-associated skin and soft tissue infections
- Streptococcus anginosus Pyomyositis in a 50-Year-Old Man with Acquired Immunodeficiency Syndrome
- Antibiotic resistance determinants in Acinetobacter spp and clinical outcomes
- Influenza-Induced Production of Interferon-Alpha is Defective in Geriatric Individuals
- Enhancing resistance to cephalosporins in class C beta-lactamases
- Three decades of beta-lactamase inhibitors
- In vitro activity of fosfomycin against blaKPC-containing Klebsiella pneumoniae isolates
- Persistence of skin contamination & environmental shedding of Clostridium difficile
- Comparative description of haplotype structure and genetic diversity of MDR1
- Inhibition of the class C beta-lactamase from Acinetobacter spp.: insights into effective inhibitor design
- Inhibitor resistance in the KPC-2 beta-lactamase, a preeminent property of this class A beta-lactamase
- Increased tissue factor expression on circulating monocytes in chronic HIV infection
- Faculty
- Research
- The Fight Against TB
- Patient Care
- Fellowship Program
- Contacts
